Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Lancet Gastroenterol Hepatol. 2018 Aug 17;3(11):742–753. doi: 10.1016/S2468-1253(18)30231-0

Figure 3. Comparative efficacy and tolerability of induction therapy for mild-to-moderate ulcerative colitis.

Figure 3.

Comparisons should be read from left to right. Odds ratio for comparisons are in the cell in common between the column-defining and row-defining treatment. Bold numbers with darker background are statistically significant; values that were borderline significant are in a lighter shade. For risk of failing to achieve clinical remission, odds ratio <1 favors row-defining treatment. For risk of drug discontinuation (tolerability), odds ratio <1 favors column-defining treatment. The numbers in parentheses represents 95% confidence intervals